Skip to main content
SYNTARA LIMITED logo

SYNTARA LIMITED — Investor Relations & Filings

Ticker · SNT ISIN · AU0000312480 LEI · 52990054L6XWT345FW20 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,620 across all filing types
Latest filing 2008-02-04 Regulatory Filings
Country AU Australia
Listing ASX SNT

About SYNTARA LIMITED

https://syntaratx.com.au/

Syntara Limited is a clinical-stage drug development company focused on the discovery and development of novel small molecule therapeutics for inflammatory and fibrotic diseases. The company specializes in the inhibition of amine oxidase enzymes, including lysyl oxidase (LOX) and semicarbazide-sensitive amine oxidase (SSAO). Its primary clinical focus is on hematological malignancies and multi-organ fibrosis. The lead drug candidate, PXS-5505, is a pan-LOX inhibitor currently being evaluated for the treatment of myelofibrosis. Additionally, the company develops treatments for skin scarring, pulmonary fibrosis, and neurodegenerative conditions. Syntara leverages its proprietary drug discovery platform to address significant unmet medical needs through targeted enzymatic inhibition, aiming to modify disease progression in complex pathological environments.

Recent filings

Filing Released Lang Actions
Investor Conference Call 1 page ?Kb
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 5 February 2008 about an upcoming investor conference call hosted by Pharmaxis Ltd to discuss the December 2007 Quarterly Report. It provides details on the timing, access numbers, and where a recording will be available. The text does not contain any actual financial data or the report itself, but rather announces the event and the forthcoming release of the quarterly report. The document length is only 1348 characters, which is quite short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Call Transcript (CT) announcement or a Regulatory Filing (RNS). However, since it is announcing a conference call and not the transcript itself, and it is not the earnings release itself, the best fit is Regulatory Filings (RNS) as a general announcement about the call and report release. Confidence is high due to clear indicators and short length.
2008-02-04 English
Appendix 4C - quarterly 5 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Appendix 4C Quarterly report for entities admitted on the basis of commitments' and contains detailed financial data including consolidated cash flow statements, cash reconciliation, financing activities, and payments to directors. It covers a quarter ended 31 December 2007 and includes substantive financial data and analysis for that period. The document is over 7,000 characters, indicating it is a full report rather than a brief announcement. The content aligns with a quarterly financial report rather than an annual report or earnings release. The presence of detailed cash flow statements and notes confirms it is an Interim / Quarterly Report (IR). Q2 2007
2008-01-24 English
Pharmaxis Aridol Gains First Asian Approval 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a media release announcing the regulatory approval of Pharmaxis' product Aridol in Korea. It is a corporate announcement about a product milestone and market expansion, not a financial report, earnings release, or regulatory filing. The text does not contain financial statements, management discussion, or voting results. It is a typical press release about a product approval and market update. Therefore, it fits best under the category of a general Regulatory Filing (RNS) as it is a regulatory announcement but not a formal financial or governance report.
2008-01-16 English
Appendix 3B - Option Exercise 10 pages ?Kb
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of ordinary shares upon exercise of options under an employee option plan, including the number of securities issued, issue price, and terms. The document references ASX rules and is a formal announcement related to securities issuance and quotation. It does not contain financial statements or management discussion but is a regulatory announcement about capital changes. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed information about securities issued, consistent with a capital change announcement rather than a brief notice or a full financial report.
2007-12-19 English
Appendix 3B - Option Issue 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B' and is described as a 'New issue announcement, application for quotation of additional securities and agreement.' It details the issuance of unlisted employee options, including exercise prices, expiry dates, vesting conditions, and the number of securities issued. The document references ASX rules and is clearly an announcement related to securities issuance and quotation. There is no indication of financial statements, management discussion, or detailed financial results. The content aligns with announcements about new share issues or capital changes rather than a full report or regulatory filing. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2007-12-19 English
Board Change 1 page ?Kb
Board/Management Information Classification · 100% confidence The document is a media release announcing a change in the company's board of directors, specifically the retirement of Mr. Charles Kiefel and the ongoing board transition. It does not contain financial data, audit information, or detailed reports. It is not an announcement of voting results, nor a regulatory filing or report publication announcement. The content clearly fits the category of Board/Management Information as it relates to changes in the company's board of directors.
2007-12-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.